ANALYSIS OF SOLUBLE FIBRIN MONOMER AS DIAGNOSTIC MARKER FOR ACUTE MYOCARDIAL INFARCTION AND ITS CORRELATION WITH CARDIAC TROPONIN I

Maimun Zulhaidah Arthamin, Lydiana Parmadi, Dwi Priyadi Djamtko, Elvin Richela Lawanto

Department of Clinical Pathology, Faculty of Medicine, Brawijaya University/dr. Saiful Anwar General Hospital, Malang, Indonesia. E-mail: maimun70@yahoo.com

ABSTRACT

The diagnosis of non-ST-Segment Elevation Myocardial Infarction (NSTEMI) is required to be early and accurate to avoid missing diagnosis and improve the rule out of Acute Myocardial Infarction (AMI) patients. There is a relationship between AMI and the state of hypercoagulation and/or thrombosis process. sFM is a prothrombotic marker found to be associated with early AMI incidence compared to cTnI, which is increased after myonecrosis. This study aimed to evaluate whether sFM can be used as a biomarker for AMI and its correlation with cTnI. A cross-sectional analytic observational study was conducted among 23 AMI patients and 27 healthy controls. Acute myocardial infarction was established using clinical, ECG, and laboratory findings. sFM levels were measured with Stago Compact Max analyzer. Statistical analysis was performed using the Spearman’s correlation coefficient, ROC curve analysis, and 2x2 contingency table. A significant correlation was found between the sFM and the cTnI (r=0.422, p<0.05). With an sFM cut-off level of 2.56 µg/mL, AMI could be diagnosed with sensitivity and specificity of 82.6% and 40.7%, respectively (AUC=0.638). sFM can be considered as a parameter of AMI. Similar studies with a cohort method involving a large number may be needed in the future study.

Key words: sFM, AMI, cTnI

INTRODUCTION

Acute Myocardial Infarction (AMI) occurs due to thrombus obstruction in the coronary artery.¹ Plaque rupture causes subendothelial exposure, which results in tissue factor interacting with factor VII and activating factor X, which will activate prothrombin become thrombin.² There is a correlation between AMI, Coronary Artery Disease (CAD), and hypercoagulation state and/or thrombosis process. In this context, several prothrombotic markers are found to be associated with prediction, incidence, or prognosis of AMI such as Prothrombin Time (PT) and Activated Partial Thromboplastin (APTT) time increase significantly in AMI patients. Tissue plasminogen activator and plasminogen activator inhibitor-1 increase in AMI patients and associated with prognosis.³ Pre and postoperative fibrin monomer concentration and D-dimer increase in patients with perioperative myocardial ischemia and show strong positive correlation with postoperative cTn.⁴ Thrombus precursor proteins have been proven to be associated with prognosis in patients with Acute Coronary Syndrome (ACS) such as increased soluble fibrin in AMI patients. It has the most powerful predictor value of MI at young age.⁵ holographic. Also, bedside soluble fibrin examination is useful for early identification of patients with unstable angina with non-typical electrocardiogram.⁶ Cardiac troponin (cTn) plays an important role in the diagnosis of AMI because of its specificity for heart muscle and its sensitivity to injury.⁷ Diagnosis of NSTEMI is needed earlier and accurate to avoid missing diagnosis and improve rule out of AMI patients. This criterion should be fulfilled by the introduction of a new generation of cTn examination, sensitive and high sensitivity cardiac troponin (s-cTn and hs-cTn).⁸,⁹ But the introduction of hs-Tn has raised the problem of lower diagnostic specificity because this examination is positive in various non-ischemic clinical conditions, including acute and chronic conditions, from the heart or not (cardiac or noncardiac).¹⁰ The need to distinguish true “thrombotic” MI from other causes of myocardial damage is a continuing challenge for appropriate treatment of the disease.

It is known that soluble fibrin monomer (sFM) is a new marker for systemic thrombus event. In the initial stage of coagulation, soluble fibrin monomers form complexes with fibrinogen and are called...
soluble Fibrin Monomer Complex (SFMC). Compared to other routine thromboembolic markers, sFM level has shown to be a predictor of systemic thrombus event and become a screening tool that is useful for identifying elders with an increased risk of a cardiocerebrovascular event. During the acute period MI, there is a systemic imbalance between coagulability and fibrinolysis, so further studies need to be done to know the diagnostic value of sFM in AMI diagnosis. This study aimed to determine that sFM could be used as AMI biomarker and its correlation with cTnI.

**METHODS**

This study was conducted on the Inpatients ward of Dr. Saiful Anwar General Hospital, Malang, Indonesia from March to May 2018. Sampling was done by the consecutive method. The research subjects were divided into two groups, and those were: AMI group that had been undergoing treatment at the Dr. Saiful Anwar General Hospital Malang and healthy control group. Acute myocardial infarction diagnosis was made based on the latest guidelines: history, physical examination, ECG, and laboratory examination (cTnI ≥ 1), by the cardiologists. The inclusion criteria were male or female patients aged 18-65 years with AMI. Exclusion criteria were patients suffering from malignancy, autoimmune diseases, and sepsis. Ethical clearance was conducted by Health Research Ethical Committee Medical Faculty Brawijaya University (Number 109/EC/KPEK/04/2018).

A venous blood sample was collected in 3.2% sodium citrate and plain tube after the admission of the patient to the hospital. The blood was centrifuged at 3000 rpm for 15 minutes to obtain the plasma and serum samples. Measurement of sFM level used plasma sample 3.2% sodium citrate with immunoturbidimetric assay STA-Liatest FM and STAGO COMPACT MAX analyzer (Diagnostica Stago, France). The examination was based on changes in turbidity of latex microparticle suspension measured by using a photometer. Measurement of cTnI used serum sample of venous blood with the immunochromatography method. An assessment of biomarkers, including sFM and cTnI, was performed as quickly as possible after collection.

This study was an analytic observational cross-sectional. Data from this study would be analyzed statistically. Data normality test used Shapiro-Wilk after that univariate analysis was performed to determine the frequency distribution of an independent variable; those were the mean of cTnI and dependent variable, which was the mean of sFM. Data were then analyzed using SPSS computer software ver. 20. Bivariate analysis used with the Spearman test analysis technique to test the correlation between sFM and cTnI. The differential test of sFM between AMI patients and healthy controls used Mann-Whitney U Test. sFM diagnosis test used ROC curve analysis and 2x2 table with cTnI as a gold standard. P-values of 0.05 were considered statistically significant.

**RESULTS AND DISCUSSION**

There were 50 subjects in this study, 23 (46%) patients with AMI, and 27 (54%) healthy control subjects. Table 1 summarizes the characteristics of the research subjects.

Gender majority of AMI patients in this study were male (14; 60.87%). There was no significant difference between the age of a patient with AMI and healthy controls. Patients diagnosed with AMI had an average age of 58.48 years. Those characteristics illustrated followed sFM study on AMI that was carried out before by Ieko et al.

A data normality test using Shapiro-Wilk generated p-value <0.05 in sFM and cTnI data. There was a significant correlation between sFM and cTnI (p < 0.05; r = 0.422) in AMI patients and healthy controls.

**Table 1. Characteristic differences between AMI and control groups**

<table>
<thead>
<tr>
<th>AMI</th>
<th>Healthy control</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M = 14</td>
<td>M = 16</td>
<td></td>
</tr>
<tr>
<td>F = 9</td>
<td>F = 11</td>
<td></td>
</tr>
<tr>
<td>Age (Mean (SD), year)</td>
<td>58.48 (14.39)</td>
<td>47.48 (18.46)</td>
</tr>
<tr>
<td>sFM (Mean (SD) µg/mL)#</td>
<td>4.13 (3.38)</td>
<td>2.91 (0.95)</td>
</tr>
<tr>
<td>cTnI (Mean (SD) ratio)#</td>
<td>18.86 (9.83)</td>
<td>0.51 (0.24)</td>
</tr>
</tbody>
</table>

AMI: Acute Myocardial Infarction; sFM: Soluble Fibrin Monomer; cTnI: Cardiac Troponin I

# p < 0.05
controls, and the correlation was moderate. There was a significant difference between sFM level in AMI patients and healthy controls (p < 0.05). ROC curve analysis in this study showed the ability of sFM in the diagnosis of AMI with AUC value 0.638 (Figure 1). The sensitivity and specificity of sFM with a cut-off of 2.56 μg/mL for AMI are 82.6 and 40.7%, respectively. Low specificity in this study was caused by difficulty to get early chest pain patients who had not been accompanied by troponin increment. This was in accordance with the study of Elged et al., where in the study, patients that are included in the study were patients with acute chest pain within the first 3 hours of the attack, so that obtained the sensitivity and specificity for sFM at a cut-off value of 8.2 μ/mL were 87.1% and 90.0% respectively while for troponin at a cut-off value of 18 ng/L were 91.4% and 85.0%. There was a correlation between AMI and hypercoagulation state and/or thrombosis process. sFM is a prothrombotic marker that is found to be associated with the initial occurrence of AMI compared to cTnI, which will be increasing recently after the occurrence of myonecrosis. sFM is a new marker for the systemic thrombus event, both heart, and non-heart (cardiac and noncardiac). More samples were needed to further prove sFM as an early marker of thrombosis occurrence in AMI.

**CONCLUSION AND SUGGESTION**

sFM is considered as an alternative parameter of AMI. There was significant correlation between sFM and cTnI (p < 0.05; r = 0.422) in AMI patients and healthy controls. The sensitivity and specificity of sFM with the cut-off 2.56 μg/mL for AMI were 82.6% and 40.7%, respectively (AUC = 0.638). Diagnosis test of sFM with cohort method and a larger number of samples is needed in future studies.

**Acknowledgment**

The authors acknowledge STAGO and DMC company for the supporting reagents and instrument.

**REFERENCES**

1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Writing group on behalf of the joint


